David Savello
Consulente / Consigliere presso Pappas Capital LLC
Profilo
Dave joined Pappas Capital in 2002 as a member of our Scientific Advisory Board, becoming a Venture Advisor in 2012.
He regularly provides clinical development guidance to our portfolio companies – including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals, where he was a member of the board of directors prior to its acquisition by Shire in 2014.
Dave was most recently Senior Vice President of Development Operations for Xenoport.
Prior to Xenoport, he co-founded NDA Partners, a drug development consulting company.
Prior to NDA Partners, he was Chief Scientific Officer for Cardinal Health, and before that, Senior Vice President for Drug Development at Guilford Pharmaceuticals.
He held senior level positions in drug development and regulatory affairs at Glaxo and Glaxo Wellcome, including Vice President for North American Regulatory Affairs.
Prior to Glaxo, Dave held positions with Warner Lambert Corporation, Boehringer Ingelheim and Riker Laboratories.
Dave served on the North Carolina State University School of Physical and Mathematical Science Foundation Board, and the University of Maryland School of Pharmacy Advisory Committee.
He previously served as a director for Panacos Pharmaceuticals, a Pappas Ventures I portfolio company.
Posizioni attive di David Savello
| Società | Posizione | Inizio |
|---|---|---|
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Consulente / Consigliere | 01/01/2002 |
Precedenti posizioni note di David Savello
| Società | Posizione | Fine |
|---|---|---|
| CARDINAL HEALTH, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2005 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01/01/1999 |
| Glaxo, Inc. | Responsabile della Conformità | 01/01/1997 |
| Glaxo Wellcome, Inc. | Responsabile della Conformità | 01/01/1997 |
| University of Maryland School of Pharmacy | Consulente / Consigliere | - |
Formazione di David Savello
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
| University of Maryland School of Pharmacy | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| PANACOS PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 9 |
|---|---|
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| Glaxo, Inc. | |
| Glaxo Wellcome, Inc. | Health Technology |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Commercial Services |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
- Borsa valori
- Insiders
- David Savello
